Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07356544 | Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC(HEROS) | recruiting | — | 50 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07452003 | An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 |
| Mar 5, 2026 |
| clinicaltrials |
| NCT05068232 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | recruiting | Phase 2 | 49 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06950073 | Curatively Intended Thoracic Reirradiation(CureLung) | recruiting | — | 500 | University of AarhusOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07174908 | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | recruiting | Phase 3 | 400 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07219251 | Engagement of Veterans With Lung Cancer(EVLC) | recruiting | N/A | 194 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07274813 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors | recruiting | Early Phase 1 | 254 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07444281 | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer | recruiting | Phase 1 | 24 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06275360 | Repositioning Immunotherapy in VetArans With Lung Cancer(RIVAL) | recruiting | Phase 2 | 25 | VA Office of Research and DevelopmentFED | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06663306 | Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC | recruiting | Phase 1 | 19 | Shanghai Chest HospitalOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT07441941 | Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup(SPARROW) | recruiting | — | 190 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03535545 | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | recruiting | Phase 1 | 100 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04485286 | Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | recruiting | Phase 2 | 72 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05452005 | Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 | 20 | University of California, DavisOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06228482 | Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 | recruiting | Phase 1 | 40 | University of California, DavisOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06905197 | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | recruiting | Phase 1 | 140 | Dizal PharmaceuticalsINDUSTRY | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07225036 | Promoting Immunotherapy Efficacy With Low-Dose Liver RT(PRIME-LRT) | recruiting | N/A | 21 | Jordan KharofaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439991 | Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery | recruiting | — | 900 | The First Hospital of Jilin UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05521789 | Erector Spinae Block for Thoracic Surgery | recruiting | Phase 4 | 70 | George Washington UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07434518 | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | recruiting | — | 500 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04676828 | Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer(ASPECT) | recruiting | N/A | 90 | University of AarhusOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05857995 | Precision Lung Cancer Survivorship Care Intervention(KYLEADSII) | recruiting | N/A | 300 | Jerod L Stapleton, PhDOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05898594 | Lung Cancer Screening in High-risk Black Individuals | recruiting | N/A | 900 | Massachusetts General HospitalOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05974150 | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | recruiting | — | 25 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07425795 | Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Chongqing University Cancer HospitalOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07427537 | Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients(miR-CIPN#1) | recruiting | N/A | 90 | University Hospital, Clermont-FerrandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07428044 | A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 23, 2026 | clinicaltrials |
| NCT03042221 | Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy | recruiting | — | 100 | University of Colorado, DenverOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423169 | Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer | recruiting | N/A | 10 | Karl Landsteiner University of Health SciencesOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06715579 | Cardiac Angiosarcoma International Registry(CAIR) | recruiting | — | 500 | Immune Oncology Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07418450 | Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary? | recruiting | N/A | 30 | University of ViennaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05557474 | Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit | recruiting | — | 236 | Chung Shan Medical UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05572944 | Formatting the Risk Prediction Models for Never-Smoking Lung Cancer(FORMOSA) | recruiting | — | 10,000 | Chung Shan Medical UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05103683 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | recruiting | Phase 1 | 90 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 5, 2026source: clinicaltrials